Search results for " FOLLOW-UP"

showing 10 items of 229 documents

Outcome of patients with CML treated with dasatinib or nilotinib after failure of second prior TKIs.

2010

Abstract Abstract 2294 Background. The TKIs Nilotinib and Dasatinib offer additional therapeutic options for patients with CML who are resistant or intolerant to Imatinib. These agents, active against the majority of Imatinib resistant BCR-ABL mutated clones, have a different pattern of kinase target selectivity, pharmacokinetics parameters, cell uptake, efflux properties and adverse events profiles. Preliminary results suggest that some patients may respond to a second TKI used as third line therapy, but little is known about the long term benefit of such an approach.Aim of this collaborative Italian study was to verify the response (rate and duration) and the clinical outcome in patients …

Oncologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyComplete blood countAlpha interferonImatinibCell BiologyHematologyGene mutationBiochemistrySurgeryDasatinibNilotinibMedian follow-upInternal medicinemedicineAdverse effectbusinessmedicine.drug
researchProduct

Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary to…

2015

To investigate the feasibility and tolerance in the use of adjuvant intensity modulated radiation therapy (IMRT) and simultaneous integrated boost in patients with a diagnosis of breast cancer after breast-conserving surgery.Between September 2011 to February 2013, 112 women with a diagnosis of early breast cancer (T1-2, N0-1, M0) were treated with IMRT and simultaneous integrated boost after breast-conserving surgery in our institution. A dose of 50Gy in 25 fractions was prescribed to the whole breast and an additional dose of radiation was prescribed on the tumour bed. A dose prescription of 60Gy in 25 fractions to the tumour bed was used in patients with negative margins after surgery, w…

Oncologymedicine.medical_treatmentSegmentalMastectomy SegmentalSeverity of Illness IndexBreast cancerNuclear Medicine and ImagingDuctalIntensity-Modulated80 and overBreastMastectomyAdjuvantEarly breast cancerAged 80 and overCarcinoma Ductal BreastSIBRadiotherapy DosageMiddle AgedOncologyBreast cancer; IMRT; SIB; Toxicity; Adult; Aged; Aged 80 and over; Breast Neoplasms; Carcinoma Ductal Breast; Carcinoma Lobular; Esthetics; Feasibility Studies; Female; Follow-Up Studies; Humans; Mastectomy Segmental; Middle Aged; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Adjuvant; Severity of Illness Index; Radiotherapy Intensity-Modulated; Oncology; Radiology Nuclear Medicine and ImagingToxicityFemaleRadiologyRadiodermatitisRadiologyAdjuvantSimultaneous integrated boostAdultmedicine.medical_specialtyEstheticsBreast NeoplasmsLobularBreast cancerInternal medicineSeverity of illnessmedicineHumansRadiology Nuclear Medicine and imagingIMRTAgedToxicityRadiotherapybusiness.industryCarcinomaIntensity-modulated radiation therapymedicine.diseaseAcute toxicityBreast cancer; IMRT; SIB; Toxicity; Oncology; Radiology Nuclear Medicine and ImagingCarcinoma LobularFeasibility StudiesRadiotherapy AdjuvantRadiotherapy Intensity-ModulatedbusinessFollow-Up Studies
researchProduct

A fast algorithm for muon track reconstruction and its application to the ANTARES neutrino telescope.

2011

An algorithm is presented, that provides a fast and robust reconstruction of neutrino induced upward-going muons and a discrimination of these events from downward-going atmospheric muon background in data collected by the ANTARES neutrino telescope. The algorithm consists of a hit merging and hit selection procedure followed by fitting steps for a track hypothesis and a point-like light source. It is particularly well-suited for real time applications such as online monitoring and fast triggering of optical follow-up observations for multi-messenger studies. The performance of the algorithm is evaluated with Monte Carlo simulations and various distributions are compared with that obtained …

Optical telescopesAMANDASelection proceduresRobust reconstructionMonte Carlo methodAtmospheric muonsReal-time applicationNeutrino telescope01 natural sciencesHigh Energy Physics - ExperimentFast algorithmsHigh Energy Physics - Experiment (hep-ex)High Energy Astrophysical Phenomena (astro-ph.HE)PhysicsDetectorMonte Carlo SimulationMonte Carlo methodsComputer simulationLIGHTddc:540Física nuclearNeutrinoAstrophysics - Instrumentation and Methods for AstrophysicsAstrophysics - High Energy Astrophysical PhenomenaAlgorithmAlgorithmsFLUXOnline monitoring[PHYS.ASTR.IM]Physics [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]Astrophysics::High Energy Astrophysical PhenomenaNeutrino telescopeFOS: Physical sciencesTrack reconstructionOptical telescopeNuclear physicsMuon tracks0103 physical sciencesAngular resolutionLight sources010306 general physicsOptical follow-upDETECTORInstrumentation and Methods for Astrophysics (astro-ph.IM)MuonANTARESneutrino telescope; track reconstruction010308 nuclear & particles physicsCharged particlesTrack (disk drive)track reconstructionAstronomy and Astrophysics[SDU.ASTR.IM]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]Physics - Data Analysis Statistics and ProbabilityFISICA APLICADAATMOSPHERIC NEUTRINOSNeutrino telescopesSYSTEMData Analysis Statistics and Probability (physics.data-an)
researchProduct

The ANTARES telescope neutrino alert system

2012

The ANTARES telescope has the capability to detect neutrinos produced in astrophysical transient sources. Potential sources include gamma-ray bursts, core collapse supernovae, and flaring active galactic nuclei. To enhance the sensitivity of ANTARES to such sources, a new detection method based on coincident observations of neutrinos and optical signals has been developed. A fast online muon track reconstruction is used to trigger a network of small automatic optical telescopes. Such alerts are generated for special events, such as two or more neutrinos, coincident in time and direction, or single neutrinos of very high energy.

Optical telescopesPhysics::Instrumentation and DetectorsAstrophysics7. Clean energy01 natural sciencesGamma ray burstsFOLLOW-UP OBSERVATIONSlaw.inventionlawFlaring activeVery high energiesHigh Energy Astrophysical Phenomena (astro-ph.HE)PhysicsGAMMA-RAY BURSTS[SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph][SDU.ASTR.HE]Sciences of the Universe [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE]Astrophysics::Instrumentation and Methods for AstrophysicsSupernovaNeutrino detectorNeutrino astronomyFísica nuclearNeutrinoAstrophysics - Instrumentation and Methods for AstrophysicsAstrophysics - High Energy Astrophysical PhenomenaFLUX[PHYS.ASTR.HE]Physics [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE][PHYS.ASTR.IM]Physics [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]Astrophysics::High Energy Astrophysical PhenomenaFOS: Physical sciencesOptical telescopeTelescopeMuon tracksCoincidentSEARCHDetection methods0103 physical sciencesCore collapse supernovae010306 general physicsOptical follow-upInstrumentation and Methods for Astrophysics (astro-ph.IM)Neutronsantares; neutrino astronomy; optical follow-up; transient sourcesANTARES010308 nuclear & particles physicsGamma raysAstronomyAstronomy and AstrophysicsAlert systemsStarsTransient sources[SDU.ASTR.IM]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]Optical signalsPotential sources13. Climate actionFISICA APLICADAHigh Energy Physics::ExperimentNeutrino astronomyGamma-ray burst
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

L’otite sieromucosa ricorrente. Follow-up a 5 anni.

2005

Otite sieromucosa follow-up
researchProduct

Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration

2005

Background: Frontotemporal lobar degeneration (FTLD) may be inherited as an autosomal dominant disease. Studying patients "at risk" for developing FTLD can provide insights into the earliest onset and evolution of the disease. Method: We carried out approximately annual clinical, MRI, and neuropsychological assessments on an asymptomatic 51 year old "at risk" family member from a family with FTLD associated with ubiquitin-positive and tau-negative inclusion bodies. We used non-linear (fluid) registration of serial MRI to determine areas undergoing significant regional atrophy at different stages of the disease. Results: Over the first 26 months of the study, the patient remained asymptomati…

PaperMalePathologymedicine.medical_specialtyDiseaseNeuropsychological TestsAsymptomaticBrain mappingAtrophy Brain/pathology Brain Mapping Dementia/pathology Disease Progression Female Follow-Up Studies Humans Male Middle Aged Neuropsychological TestsAtrophymental disordersmedicineHumansDementiaBrain MappingSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaNeuropsychologyfood and beveragesnutritional and metabolic diseasesBrainAutosomal dominant traitFrontotemporal lobar degenerationMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthDisease ProgressionDementiaFemaleSurgeryNeurology (clinical)Atrophymedicine.symptomPsychologyFollow-Up Studies
researchProduct

One-Year Follow-Up Diagnostic Stability of Autism Spectrum Disorder Diagnosis in a Clinical Sample of Children and Toddlers

2020

Some studies show that the diagnosis of Autism Spectrum Disorder could be considered reliable and stable in children aged 18 to 24 months. Nevertheless, the diagnostic stability of early ASD diagnosis has not yet been fully demonstrated. This observational study examines the one-year diagnostic stability of autism spectrum disorder diagnosis in a clinical sample of 147 children diagnosed between 18 and 48 months of age. The ADOS-2 scores were used in order to stratify children in three levels of symptom severity: Autism (AD; comparison score 5–7), Autism Spectrum Disorder (ASD; comparison score 3–4), and Sub-Threshold Symptoms; (STS; comparison score 1–2). Results: Overall…

Pediatricsmedicine.medical_specialtyOne year follow upbehavioral treatmentautism spectrum disorderautism spectrum disorder; behavioral treatment; diagnostic stability; follow-upArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersfollow-upMedicine0501 psychology and cognitive scienceslcsh:Neurosciences. Biological psychiatry. Neuropsychiatrydiagnostic stabilitybusiness.industryGeneral Neuroscience05 social sciencesBehavioral treatmentSymptom severityAutism spectrum disorder Behavioral treatment Diagnostic stability Follow-upmedicine.diseaseSettore MED/39 - Neuropsichiatria InfantileAutism spectrum disorderAutismObservational studybusiness030217 neurology & neurosurgery050104 developmental & child psychologyAutistic symptomsBrain Sciences; Volume 11; Issue 1; Pages: 37
researchProduct

Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia

2016

Introduction. Since 2014 Delamanid (Dlm) was introduced in M/XDR-TB treatment under programmatic conditions. The aim of this study was to analyse experience of Dlm use. Methods. For all MDR-TB cases treatment regimens (Tx) are designed by MDR-TB expert committee. Dlm is prescribed for patients with risk of failure of Tx due to resistance or severe intolerance of key 2 nd line drugs. We analysed clinical and demographic data for all patients who received Dlm during the period of July 2014 to February 2016. Data were collected from patient9s medical records. Results. In total 20 MDR TB patients received Dlm: 3 female and 17 male with median age 46 years, including 2 children (11 and 13 years …

Pediatricsmedicine.medical_specialtybusiness.industryMedical recordPyrazinamidechemistry.chemical_compoundchemistryLevofloxacinMoxifloxacinLinezolidMedicineLost to follow-upDelamanidbusinessAdverse effectmedicine.drug10.2 Tuberculosis
researchProduct

Leukocytosis and Thrombosis At Diagnosis Are Associated with Poor Survival in Polycythemia Vera: A Population-Based Study on 327 Patients

2011

Abstract Abstract 2819 Introduction Polycythemia Vera (PV) is a myeloproliferative neoplasm with a long life expectancy. Consequently, long-term follow-up studies that focus on survival of PV patients must be conducted in order to register a sufficient number of events to provide informative results and statistical analyses. Most of the published studies are single-institution that focused on patients referred to hospitals, which does not necessarily reflect the course of PV in the general population. In these studies, the median age at diagnosis is younger than usually noted for PV patients in population-based studies. Moreover, survival is generally based on observed mortality, a good but…

Pediatricsmedicine.medical_specialtyeducation.field_of_studyMultivariate analysisRelative survivalbusiness.industryMortality rateImmunologyPopulationCell BiologyHematologyBiochemistryConfidence intervalMedian follow-upmedicineRisk factorbusinesseducationSurvival rateBlood
researchProduct